This site is intended for US audiences only.

This site is intended for US audiences only.

REVLIMID is a prescription medicine used to treat adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) in combination with a rituximab product, and who have previously been treated for their FL or MZL. FL and MZL are types of cancer of white blood cells called B-cell lymphocytes that are found in the lymph nodes and spleen. REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.

The REMS Companion App

Easily access the
Lenalidomide REMS program.

Download now

Beginning your R2
treatment journey

Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma

R2 IS A CHEMOTHERAPY-FREE COMBINATION THAT WAS TESTED IN LABORATORY STUDIES

This combination of REVLIMID and rituximab was shown to work with certain cells used by the immune system to attack the lymphoma cells.

In laboratory studies, REVLIMID and rituximab have been shown to help:

  • Reactivate certain immune cells
  • Restrict the spread of cancer cells

R2 has been studied for both
safety and effectiveness in
clinical trials

LEARN MORE
Hypothetical healthcare provider looking through a microscope
Hypothetical doctor talking to a R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma while showing them their tablet

REVLIMID + rituximab
is a chemotherapy-free
treatment

VIEW DOSING

Due to safety concerns,
you must be enrolled in the
Lenalidomide REMS program
before you begin treatment

LEARN MORE
Hypothetical R² (REVLIMID® [lenalidomide] + rituximab) patient with relapsed/refractory follicular or marginal zone lymphoma